New Chemical Entities (NCEs)
We are engaged in the discovery, development, and commercialization of novel small molecule agents to address significant clinical unmet needs. We were the first Indian pharmaceutical company to start NCE research at our Hyderabad-based research laboratory in 1993. Dr. Reddy's was also the first Indian pharmaceutical company to out-license an original molecule to an innovator pharmaceutical company in 1997. Our therapeutic areas of focus are bacterial infections, metabolic disorders, and pain/ inflammation.
Focus Therapeutic Areas
The incidence of hospital acquired infections is growing as drug-resistant bacteria are becoming even more difficult to treat. There are significant challenges in adequately treating infections caused by multi-drug resistant pathogens such as Staphylococcus Aureas, Pseudomonas Aeruginosa, and Acinetobacter Baumannii. The resultant infections are often serious and life-threatening. We are working to identify new approaches to treat these infections with products that have improved efficacy and tolerability profiles.
Globally, cardiovascular diseases are one of the leading causes of death. Many patients suffering from Cardio Vascular disease (CVD) are also afflicted with insulin resistance, Type-2 Diabetes, Dyslipidemia, and obesity. While there are several treatment options for a few of these conditions, a need persists for effective and safe therapies that address insulin resistance, obesity, low HDL cholesterol and Atherosclerosis. We have several programs targeting one or more of these disease conditions.
Pain / Inflammation:
The prevalence of chronic and acute pain is growing steadily as our population ages and diagnosis rates improve. Although there are a number of medications to treat chronic and acute pain, new treatments that are both safe and tolerable remain essential. We are developing products with improved efficacy and side-effect profiles in several areas of acute and chronic pain.